Loading clinical trials...
Loading clinical trials...
A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Conditions
Interventions
Azirkitug
Budigalimab
+2 more
Locations
44
United States
City of Hope National Medical Center /ID# 276272
Duarte, California, United States
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589
Irvine, California, United States
University of Illinois Hospital and Health Sciences System /ID# 251750
Chicago, Illinois, United States
Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593
Fort Wayne, Indiana, United States
Community Health Network, Inc. /ID# 243011
Indianapolis, Indiana, United States
Norton Cancer Institute /ID# 248903
Louisville, Kentucky, United States
Start Date
November 1, 2021
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
April 13, 2026
NCT06532279
NCT07431827
NCT06758401
NCT06427941
NCT06476808
NCT07164313
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions